NanoViricides, Inc. (NNVC)
1.44
-0.07
(-4.64%)
USD |
NYAM |
Oct 22, 15:40
NanoViricides Enterprise Value : 31.95M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | 31.95M |
| October 20, 2026 | 31.26M |
| October 19, 2026 | 27.12M |
| October 16, 2026 | 28.96M |
| October 15, 2026 | 28.73M |
| October 14, 2026 | 27.35M |
| October 13, 2026 | 27.58M |
| October 12, 2026 | 26.66M |
| October 09, 2026 | 27.12M |
| October 08, 2026 | 27.35M |
| October 07, 2026 | 30.34M |
| October 06, 2026 | 29.42M |
| October 05, 2026 | 30.57M |
| October 02, 2026 | 26.66M |
| October 01, 2026 | 26.20M |
| September 30, 2026 | 27.12M |
| September 29, 2026 | 27.12M |
| September 28, 2026 | 31.72M |
| September 25, 2026 | 30.34M |
| September 24, 2026 | 30.34M |
| September 23, 2026 | 31.95M |
| September 22, 2026 | 32.41M |
| September 21, 2026 | 36.09M |
| September 18, 2026 | 29.88M |
| September 17, 2026 | 29.42M |
| Date | Value |
|---|---|
| September 16, 2026 | 24.82M |
| September 15, 2026 | 21.36M |
| September 14, 2026 | 21.36M |
| September 11, 2026 | 20.67M |
| September 10, 2026 | 20.67M |
| September 09, 2026 | 21.13M |
| September 08, 2026 | 22.05M |
| September 04, 2026 | 22.98M |
| September 03, 2026 | 23.67M |
| September 02, 2026 | 24.13M |
| September 01, 2026 | 25.05M |
| August 31, 2026 | 25.97M |
| August 28, 2026 | 25.74M |
| August 27, 2026 | 26.66M |
| August 26, 2026 | 26.66M |
| August 25, 2026 | 26.89M |
| August 24, 2026 | 26.43M |
| August 21, 2026 | 27.81M |
| August 20, 2026 | 27.35M |
| August 19, 2026 | 28.04M |
| August 18, 2026 | 28.27M |
| August 17, 2026 | 28.50M |
| August 14, 2026 | 28.96M |
| August 13, 2026 | 28.50M |
| August 12, 2026 | 28.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.593B |
| Alnylam Pharmaceuticals, Inc. | 29.78B |
| Anika Therapeutics, Inc. | 262.53M |
| Savara, Inc. | 816.59M |
| Vericel Corp. | 2.027B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.223M |
| Total Expenses (Quarterly) | 2.223M |
| EPS Diluted (Quarterly) | -0.0996 |
| Earnings Yield | -28.34% |
| Normalized Earnings Yield | -28.34 |